Table 2.

Differences in time to target not detected (TND), HCV clearance in extracellular body fluid (CL-EF) and HCV-infected hepatocytes clearance (CL-C) according to baseline clinical and virological characteristics.

Variable	Time to TND (weeks)Ω	p*	CL-EF (weeks) Ω	p*	CL-C (weeks) Ω	p*
Gender Male vs female	2 (1–4) vs 2 (1–4)	0.924	6 (5–8) vs 6 (4–8)	0.822	8 (6–10) vs 8 (5–10)	0.782
Baseline VL ≤ 5 vs >5 (log)	2 (1–2) vs 3 (2–5)	<0.001	5 (3–6) vs 7 (5–8)	<0.001	7 (5–9) vs 9 (8–12)	<0.001
HCC Present vs absent	2 (1–4) vs 2 (2–4)	0.922	6 (4–8) vs 6 (3–8)	0.752	8 (6–10) vs 8 (5–10)	0.752
Child Pugh ≤7 vs > 7	2 (1–3) vs 3 (1–4)	0.234	6 (4–7) vs 8 (5–10)	0.016	7 (5–9) vs 9 (6–13)	0.029
MELD <15 vs ≥15	2 (1.5–4) vs 2 (1–3)	0.814	6 (4–8) vs 6 (4–8)	0.904	8 (6–10) vs 8 (5–10)	0.831
LSM LSM <21 kPa vs ≥21 kPa	2 (1–3) vs 2.5 (2–5)	0.009	5 (3–7) vs 6 (5–9)	0.016	7 (5–9) vs 8 (7–11)	0.047
HVPG <10 vs vs ≥ 10 mmHg <12 vs vs ≥ 12 mmHg	2 (1–5) vs 2 (1–3) 2 (1–3) vs 2 (1–3)	0.860 0.499	5 (3–7) vs 5 (4–7) 5 (3–7) vs 5 (4–7)	0.596 0.417	7 (4–9) vs 7 (5–9) 7 (5–9) vs 7 (5–9)	0.654 0.494
Plt count <100.000 vs ≥100.000/mm3	2 (1–3) vs 2 (2–4)	0.126	5 (3–7) vs 6 (5–8)	0.119	7 (5–9) vs 9 (6–11)	0.215
Albumin <35 vs ≥ 35 g/L	2 (1–4) vs 2 (2–4)	0.752	5 (4–7) vs 6 (5–8)	0.191	7 (5–9) vs 8 (6–11)	0.282
IL28 polymorphism Non-favorable vs favorable	2 (2–3) vs 2 (1–4)	0.779	6 (6–8) vs 6 (4–7)	0.882	7 (6–11) vs 8 (5–9)	0.753
DAA regimen SOF+SMV±RBV DCV+SMV±RBV DCV+SOF±RBV OBV+PTV/r/DSV±RBV SOF+LDV±RBV	2 (2–4) 3 (2–5) 2 (2–5) 2 (1–3) 2 (1–3)	0.218	6 (2–12) 6 (3–7) 7 (5–10) 5 (4–6) 4 (3–8)	0.362	8 (3–17) 7 (5–9) 9 (7–13) 8 (3–11) 6 (4–13)	0.495

TND: target non detected, HVPG: hepatic venous pressure gradient, LSM: liver stiffness measurement, HCC: hepatocellular carcinoma, DAA: direct acting antivirals, Plt: platelet.

^*Univariate analysis

^ΩData is expressed as median and IQR.